5,045 trials (keyword fallback)
Ebola
Primary: Mean Assay Negativity Rate (ANR) for Ebola Virus During the Treatment Phase — 0.85; 0.76 proportion of semen samples
Tuberculosis
Primary: Number of Subjects With Grade 3 Solicited Local Symptoms — 1; 0; 1; 0 Participants
Chronic Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12) — 96.3 percentage of participants
Hepatitis C Virus (HCV)
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 99.4 percentage of participants
Hepatitis C Infection With HIV Co-Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Completion of Treatment (SVR12) — 76.9 percentage of participants
Hepatitis C Virus (HCV)
Primary: Percentage of HCV GT1 - GT6-Infected Participants in Arm A Who Achieved Sustained Virologic Response 12 Weeks Post Treatment (SVR12) — 97.2 percentage of participants
Hepatitis C Virus Infection · Human Immunodeficiency Virus Infection · Chronic Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 98.0 percentage of participants
Human Immunodeficiency Virus-Infection
Primary: Aspartate Aminotransferase (AST) / Alanine Aminotransferase (ALT) Parameters — 64; 69 U/liter
HIV · HIV Infections
Primary: Percentage of Participants With ≥1 Adverse Events (AEs) — 91 Percentage of Participants
Anal Neoplasm
Primary: Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL and no Evidence of HPV-16/18 at Week 36 — 9.1 percentage of participants — p=0.8633
Healthy Participants
Primary: Percentage of Participants With Positive Responses in Virus-specific Antibody in Sera — 80; 75; 100; 100 percentage of participants
HIV
Primary: Change in Human Immunodeficiency Virus 1 (HIV-1) Ribonucleic Acid (RNA) Levels — 0; 0; -0.03; -0.08 Log10 copies/ml plasma
HIV Infection
Primary: Pre- and Post- Interferon Alpha on Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) — 670; 180; 90; 130 # of copies of HIV RNA/million cells
Hepatitis C Virus Genotype-1
Primary: Percentage of Participants With Sustained Virologic Response at Week 12 (SVR 12) — 73.6 percentage of participants
HIV · AIDS · Opioid Dependence
Primary: Participants Who Had Undetectable HIV-1 RNA Levels at Less Than 400 Copies/mL at Six Month — 45; 16 Participants — p=0.431